Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757230 | 0.85 | CNR1 (0.42) | CNR1ALDH1A1CNR2DPP4MAPT | |
| SCHEMBL5758338 | 0.82 | ADORA2A (0.43) | CNR1ALDH1A1CNR2MAPTSLC6A4 | |
| SCHEMBL5757516 | 0.81 | CXCR2 (0.47) | CNR1ALDH1A1CNR2DPP4MAPT | |
| SCHEMBL5756347 | 0.79 | NPY5R (0.47) | HPGDS | |
| SCHEMBL5756845 | 0.78 | SCN2A (0.44) | DPP4EGFR | |
| SCHEMBL5758675 | 0.77 | SCN2A (0.54) | HPGDS | |
| SCHEMBL5757793 | 0.75 | ALDH1A1 (0.45) | CNR1ALDH1A1CNR2MAPTKDM4E | |
| SCHEMBL5756074 | 0.73 | SCN2A (0.49) | HPGDS | |
| SCHEMBL5758137 | 0.72 | SCN2A (0.62) | HPGDS | |
| SCHEMBL5758399 | 0.71 | SCN2A (0.47) | MAPTHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | claimed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | claimed |
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | disclosed |
| US-6673941-B2 | Disubstituted imidazoles useful in the treatment of bacterial infections | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-01-06 | — | — | US | disclosed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | disclosed |
| US-6559172-B1 | Treatment of bacterial infections, particularly through the inhibition of FAB I. and antiobiotics | SMITHKLINE BEECHAM CORPORATION | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149089-A1 | Antibacterial compounds | MRPL21, MRPS28, SPOUT1 | CNR1 1387/4885ALDH1A1 388/4885CNR2 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.